WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H123154
CAS#: 2248691-29-2
Description: ARN22089 is a CDC42 GTPase Interaction Inhibitor for the Treatment of Cancer. ARN22089 blocks tumor growth in BRAF mutant mouse melanoma models and patient-derived xenografts (PDXs) in vivo. ARN22089 also inhibits tumor angiogenesis in three-dimensional vascularized microtumor models in vitro
Hodoodo Cat#: H123154
Name: ARN22089
CAS#: 2248691-29-2
Chemical Formula: C23H27N5
Exact Mass: 373.23
Molecular Weight: 373.500
Elemental Analysis: C, 73.96; H, 7.29; N, 18.75
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ARN22089; ARN 22089; ARN-22089
IUPAC/Chemical Name: N1,N1-dimethyl-N3-(6-phenyl-2-(piperidin-4-yl)pyrimidin-4-yl)benzene-1,3-diamine
InChi Key: BWJICNGLWINASO-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H27N5/c1-28(2)20-10-6-9-19(15-20)25-22-16-21(17-7-4-3-5-8-17)26-23(27-22)18-11-13-24-14-12-18/h3-10,15-16,18,24H,11-14H2,1-2H3,(H,25,26,27)
SMILES Code: CN(C)C1=CC=CC(NC2=NC(C3CCNCC3)=NC(C4=CC=CC=C4)=C2)=C1
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 373.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Jahid S, Ortega JA, Vuong LM, Acquistapace IM, Hachey SJ, Flesher JL, La
Serra MA, Brindani N, La Sala G, Manigrasso J, Arencibia JM, Bertozzi SM, Summa
M, Bertorelli R, Armirotti A, Jin R, Liu Z, Chen CF, Edwards R, Hughes CCW, De
Vivo M, Ganesan AK. Structure-based design of CDC42 effector interaction
inhibitors for the treatment of cancer. Cell Rep. 2022 Apr 5;39(1):110641. doi:
10.1016/j.celrep.2022.110641. Erratum in: Cell Rep. 2022 Apr 26;39(4):110760.
PMID: 35385746; PMCID: PMC9127750.
2: Brindani N, Vuong LM, Acquistapace IM, La Serra MA, Ortega JA, Veronesi M,
Bertozzi SM, Summa M, Girotto S, Bertorelli R, Armirotti A, Ganesan AK, De Vivo
M. Design, Synthesis, In Vitro and In Vivo Characterization of
CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer. J Med Chem.
2023 Apr 7. doi: 10.1021/acs.jmedchem.3c00276. Epub ahead of print. PMID:
37026468.
